Combination immunotherapy: a road map

Cancer immunotherapy and in particular monoclonal antibodies blocking the inhibitory programed cell death 1 pathway (PD-1/PD-L1) have made a significant impact on the treatment of cancer patients in recent years. However, despite the remarkable clinical efficacy of these agents in a number of malign...

Descripción completa

Detalles Bibliográficos
Autores principales: Ott, Patrick A., Hodi, F. Stephen, Kaufman, Howard L., Wigginton, Jon M., Wolchok, Jedd D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319100/
https://www.ncbi.nlm.nih.gov/pubmed/28239469
http://dx.doi.org/10.1186/s40425-017-0218-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319100/
https://www.ncbi.nlm.nih.gov/pubmed/28239469
http://dx.doi.org/10.1186/s40425-017-0218-5

Ejemplares similares